BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 15309248)

  • 1. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
    Talbert RL
    Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
    Cleland JG
    Curr Heart Fail Rep; 2004 Jul; 1(2):82-8. PubMed ID: 16036030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
    Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
    Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should COMET influence heart failure practice?
    Adams KF
    Curr Heart Fail Rep; 2004 Jul; 1(2):67-71. PubMed ID: 16036027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
    McBride BF; White CM
    J Clin Pharmacol; 2005 Jan; 45(1):6-24. PubMed ID: 15601801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
    Bristow MR; Feldman AM; Adams KF; Goldstein S
    J Card Fail; 2003 Dec; 9(6):444-53. PubMed ID: 14966783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
    Poole-Wilson PA; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Metra M; J Remme W; Swedberg K; Torp-Pedersen C
    Eur J Heart Fail; 2002 Jun; 4(3):321-9. PubMed ID: 12034158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In heart failure, all beta-blockers are not necessarily equal.
    Tang WH; Militello M; Francis GS
    Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 16. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
    Packer M
    J Card Fail; 2003 Dec; 9(6):429-43. PubMed ID: 14966782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
    Swedberg K
    Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
    [No Abstract]   [Full Text] [Related]  

  • 18. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
    Doggrell SA
    Expert Opin Pharmacother; 2004 Jan; 5(1):205-8. PubMed ID: 14680448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.